

Corresponding author(s):	DUHARCOURT
Last updated by author(s):	Jan 31, 2019

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.

_					
C1	1	ŤΙ	ist	т.	$\sim c$
_) I			ואו	- 11	١,

For	all statistical analys	es, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.		
n/a	Confirmed			
	The exact sam	ple size (n) for each experimental group/condition, given as a discrete number and unit of measurement		
	A statement o	n whether measurements were taken from distinct samples or whether the same sample was measured repeatedly		
	The statistical Only common te	test(s) used AND whether they are one- or two-sided ests should be described solely by name; describe more complex techniques in the Methods section.		
\boxtimes	A description	of all covariates tested		
\boxtimes	A description	of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons		
	A full descripti AND variation	on of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)		
	For null hypot Give P values as	hesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted exact values whenever suitable.		
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings			
	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes			
	Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated			
	'	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.		
So	ftware and c	ode		
Poli	cy information abou	ut <u>availability of computer code</u>		
Data collection		Standard published procedures were used. Details and refrences are given in Methods. For MS, instrument: Q Exactive HF-X; Software Version: 2.9 SP2 Build 2947.		

Published softwares and standard packages were used. Versions are given in Methods. Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

see Data Availability section: The RNA-seq and ChIP-seq datasets generated for this study have been deposited at the ENA with Study Accession number PRJEB21555. Accession numbers are provided in Sup Table 2 (RNAseq) and Sup Table 6 (ChIPseq). The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the data set identifier PXD012170.

Field-spe	ecific r	eporting		
Please select the or	ne below that	t is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.		
X Life sciences		Behavioural & social sciences		
For a reference copy of t	the document wit	th all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>		
lifa sciar	ncas st	cudy design		
		· · · · · · · · · · · · · · · · · · ·		
All studies must dis Sample size	sclose on these points even when the disclosure is negative. Sample sizes for NGS are given in Sup Tables 2 and 6			
Data exclusions		Filtering of NGS datasets in Methods and Sup Tables 2 and 6.		
Replication	Biological rep	licates were used for all experiments.		
Randomization	NA			
Blinding	NA			
Reportin	g for s	pecific materials, systems and methods		
We require information	on from author	rs about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material,		
Materials & exp		to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. Systems Methods		
n/a Involved in th		n/a Involved in the study		
Antibodies	,	│		
Eukaryotic	cell lines	Flow cytometry		
Palaeontolo	0,	MRI-based neuroimaging		
	id other organis search participa			
Clinical dat				
Antibodies				
Antibodies used		see Methods and Sup Figure 7		
Validation		see Methods and Sup Figure 7		
ChIP-seq				
Data deposition	1			
Confirm that I	both raw and	final processed data have been deposited in a public database such as <u>GEO</u> .		
Confirm that	you have dep	osited or provided access to graph files (e.g. BED files) for the called peaks.		
Data access links May remain private be		ChIP-seq datasets generated for this study have been deposited at the ENA with Study Accession number PRJEB21555.		
Files in database	submission	see Sup Table 6		
Genome browser (e.g. <u>UCSC</u>)	r session	NA		
Methodology				

Replicates

See Sup Table 6

Sequencing depth	See Sup Table 6
Antibodies	Methods and Sup Fig 7
Peak calling parameters	NA
Data quality	see Sup Table 6
Software	see Methods.